tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2021 May 23;8(7)
fab268.
doi: 10.1093/ofid/ofab268. eCollection 2021 Jul.
Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants
Jason M Pogue[SUP] 1 [/SUP], Adam S Lauring[SUP] 2 [/SUP], Tejal N Gandhi[SUP] 2 [/SUP], Vincent D Marshall[SUP] 1 3 [/SUP], Gregory A Eschenauer[SUP] 1 [/SUP], Jerod L Nagel[SUP] 3 [/SUP], Ji Hoon Baang[SUP] 2 [/SUP], Shiwei Zhou[SUP] 2 [/SUP], Andrew L Valesano[SUP] 4 [/SUP], Lindsay A Petty[SUP] 2 [/SUP]
Affiliations
Abstract
Monoclonal antibodies targeting the receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 spike protein are important outpatient treatment options in coronavirus disease 2019 to mitigate progression of disease and prevent hospitalization. The impact of different RBD mutations on the efficacy of the available monoclonal antibodies and processes for incorporating this impact into treatment algorithms are ill defined. Herein, we synthesize the data surrounding the impact of key RBD mutations on the efficacy of US Food and Drug Administration Emergency Use Authorized monoclonal antibodies and describe our approach at Michigan Medicine at monitoring mutation frequency in circulating virus and developing an algorithm that incorporates these data into outpatient treatment pathways.
Keywords: COVID-19; SARS-CoV-2; bamlanivimab; bamlanivimab and etesevimab; casirivimab and imdevimab; variants.
. 2021 May 23;8(7)
fab268.doi: 10.1093/ofid/ofab268. eCollection 2021 Jul.
Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants
Jason M Pogue[SUP] 1 [/SUP], Adam S Lauring[SUP] 2 [/SUP], Tejal N Gandhi[SUP] 2 [/SUP], Vincent D Marshall[SUP] 1 3 [/SUP], Gregory A Eschenauer[SUP] 1 [/SUP], Jerod L Nagel[SUP] 3 [/SUP], Ji Hoon Baang[SUP] 2 [/SUP], Shiwei Zhou[SUP] 2 [/SUP], Andrew L Valesano[SUP] 4 [/SUP], Lindsay A Petty[SUP] 2 [/SUP]
Affiliations
- PMID: 34291118
- PMCID: PMC8194619
- DOI: 10.1093/ofid/ofab268
Abstract
Monoclonal antibodies targeting the receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 spike protein are important outpatient treatment options in coronavirus disease 2019 to mitigate progression of disease and prevent hospitalization. The impact of different RBD mutations on the efficacy of the available monoclonal antibodies and processes for incorporating this impact into treatment algorithms are ill defined. Herein, we synthesize the data surrounding the impact of key RBD mutations on the efficacy of US Food and Drug Administration Emergency Use Authorized monoclonal antibodies and describe our approach at Michigan Medicine at monitoring mutation frequency in circulating virus and developing an algorithm that incorporates these data into outpatient treatment pathways.
Keywords: COVID-19; SARS-CoV-2; bamlanivimab; bamlanivimab and etesevimab; casirivimab and imdevimab; variants.